Milena S Espindola1, David M Habiel1, Ana Lucia Coelho1, Barry Stripp1, William C Parks1, Justin Oldham2, Fernando J Martinez3, Imre Noth4, David Lopez5, Amanda Mikels-Vigdal5, Victoria Smith5, Cory M Hogaboam1. 1. Women's Guild Lung Institute, Pulmonary & Critical Care Medicine, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California. 2. Division of Pulmonary & Critical Care Medicine, University of California at Davis, Sacramento, California. 3. Weill Cornell Medical College, Cornell University, New York, New York. 4. Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia; and. 5. Department of Biology, Gilead Sciences, Inc., Foster City, California.
Abstract
Rationale: Aberrant lung remodeling in idiopathic pulmonary fibrosis (IPF) is characterized by elevated MMP9 (matrix metalloproteinase 9) expression, but the precise role of this matrix metalloproteinase in this disease has yet to be fully elucidated. Objectives: To evaluate antifibrotic effects of MMP9 inhibition on IPF. Methods: Quantitative genomic, proteomic, and functional analyses both in vitro and in vivo were used to determine MMP9 expression in IPF cells and the effects of MMP9 inhibition on profibrotic mechanisms.Measurements and Main Results: In the present study, we demonstrate that MMP9 expression was increased in airway basal cell (ABC)-like cells from IPF lungs compared with ABC cells from normal lungs. The inhibition of MMP9 activity with an anti-MMP9 antibody, andecaliximab, blocked TGF-β1 (transforming growth factor β1)-induced Smad2 phosphorylation. However, in a subset of cells from patients with IPF, TGF-β1 activation in their ABC-like cells was unaffected or enhanced by MMP9 blockade (i.e., nonresponders). Further analysis of nonresponder ABC-like cells treated with andecaliximab revealed an association with type 1 IFN expression, and the addition of IFNα to these cells modulated both MMP9 expression and TGF-β1 activation. Finally, the inhibition of MMP9 ameliorated pulmonary fibrosis induced by responder lung cells but not a nonresponder in a humanized immunodeficient mouse model of IPF.Conclusions: Together, these data demonstrate that MMP9 regulates the activation of ABC-like cells in IPF and that targeting this MMP might be beneficial to a subset of patients with IPF who show sufficient expression of type 1 IFNs.
Rationale: Aberrant lung remodeling in idiopathic pulmonary fibrosis (IPF) is characterized by elevated MMP9 (matrix metalloproteinase 9) expression, but the precise role of this matrix metalloproteinase in this disease has yet to be fully elucidated. Objectives: To evaluate antifibrotic effects of MMP9 inhibition on IPF. Methods: Quantitative genomic, proteomic, and functional analyses both in vitro and in vivo were used to determine MMP9 expression in IPF cells and the effects of MMP9 inhibition on profibrotic mechanisms.Measurements and Main Results: In the present study, we demonstrate that MMP9 expression was increased in airway basal cell (ABC)-like cells from IPF lungs compared with ABC cells from normal lungs. The inhibition of MMP9 activity with an anti-MMP9 antibody, andecaliximab, blocked TGF-β1 (transforming growth factor β1)-induced Smad2 phosphorylation. However, in a subset of cells from patients with IPF, TGF-β1 activation in their ABC-like cells was unaffected or enhanced by MMP9 blockade (i.e., nonresponders). Further analysis of nonresponder ABC-like cells treated with andecaliximab revealed an association with type 1 IFN expression, and the addition of IFNα to these cells modulated both MMP9 expression and TGF-β1 activation. Finally, the inhibition of MMP9 ameliorated pulmonary fibrosis induced by responder lung cells but not a nonresponder in a humanized immunodeficient mouse model of IPF.Conclusions: Together, these data demonstrate that MMP9 regulates the activation of ABC-like cells in IPF and that targeting this MMP might be beneficial to a subset of patients with IPF who show sufficient expression of type 1 IFNs.
Entities:
Keywords:
airway basal cells; andecaliximab; idiopathic pulmonary fibrosis; metalloproteinase 9; type I IFNs
Authors: Yong Huang; Shwu-Fan Ma; Milena S Espindola; Rekha Vij; Justin M Oldham; Gary B Huffnagle; John R Erb-Downward; Kevin R Flaherty; Beth B Moore; Eric S White; Tong Zhou; Jianrong Li; Yves A Lussier; MeiLan K Han; Naftali Kaminski; Joe G N Garcia; Cory M Hogaboam; Fernando J Martinez; Imre Noth Journal: Am J Respir Crit Care Med Date: 2017-07-15 Impact factor: 21.405
Authors: Philip L Molyneaux; Saffron A G Willis-Owen; Michael J Cox; Phillip James; Steven Cowman; Michael Loebinger; Andrew Blanchard; Lindsay M Edwards; Carmel Stock; Cécile Daccord; Elisabetta A Renzoni; Athol U Wells; Miriam F Moffatt; William O C Cookson; Toby M Maher Journal: Am J Respir Crit Care Med Date: 2017-06-15 Impact factor: 21.405
Authors: Willis S Bowman; Chad A Newton; Angela L Linderholm; Megan L Neely; Janelle Vu Pugashetti; Bhavika Kaul; Vivian Vo; Gabrielle A Echt; William Leon; Rupal J Shah; Yong Huang; Christine Kim Garcia; Paul J Wolters; Justin M Oldham Journal: Lancet Respir Med Date: 2022-01-18 Impact factor: 102.642